Table 2.

Treatment and Outcomes of Patients With Tuberculosis and Hemophagocytic Lymphohistiocytosis.

Treatment	n = 82
No treatment	8/82 (9.8%)
Antitubercular therapy alone	16/82 (19.5%)
Antitubercular with immunosuppressants	57/82 (69.5%)
Immunosuppressants alone	1/82 (1.2%)
Modified antitubercular therapy	11/73 (15%)
Antitubercular therapy initiated first	11/44 (40.9%)
Immunosuppressant initiated first	11/44 (25%)
Antitubercular and immunosuppressant started together	15/44 (34.1%)
Death	37/82 (45.1%)